CN102655746B - 亚氨基糖以及治疗病毒性疾病的方法 - Google Patents

亚氨基糖以及治疗病毒性疾病的方法 Download PDF

Info

Publication number
CN102655746B
CN102655746B CN201080017591.3A CN201080017591A CN102655746B CN 102655746 B CN102655746 B CN 102655746B CN 201080017591 A CN201080017591 A CN 201080017591A CN 102655746 B CN102655746 B CN 102655746B
Authority
CN
China
Prior art keywords
dnj
virus
cells
dengue
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080017591.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102655746A (zh
Inventor
厄本·拉姆斯泰特
布伦南·克洛斯
妮科尔·齐兹曼
雷蒙德·A·德韦克
特里·D·巴特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imogen Ghent Virology LLC
University of Oxford
Original Assignee
University of Oxford
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oxford, United Therapeutics Corp filed Critical University of Oxford
Priority to CN201610416182.XA priority Critical patent/CN106420740A/zh
Publication of CN102655746A publication Critical patent/CN102655746A/zh
Application granted granted Critical
Publication of CN102655746B publication Critical patent/CN102655746B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
CN201080017591.3A 2009-02-23 2010-02-22 亚氨基糖以及治疗病毒性疾病的方法 Expired - Fee Related CN102655746B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610416182.XA CN106420740A (zh) 2009-02-23 2010-02-22 亚氨基糖以及治疗病毒性疾病的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20236709P 2009-02-23 2009-02-23
US61/202,367 2009-02-23
US27225509P 2009-09-04 2009-09-04
US61/272,255 2009-09-04
PCT/US2010/024920 WO2010096764A1 (en) 2009-02-23 2010-02-22 Iminosugars and methods of treating viral diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610416182.XA Division CN106420740A (zh) 2009-02-23 2010-02-22 亚氨基糖以及治疗病毒性疾病的方法

Publications (2)

Publication Number Publication Date
CN102655746A CN102655746A (zh) 2012-09-05
CN102655746B true CN102655746B (zh) 2016-08-03

Family

ID=42634239

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080017591.3A Expired - Fee Related CN102655746B (zh) 2009-02-23 2010-02-22 亚氨基糖以及治疗病毒性疾病的方法
CN201610416182.XA Pending CN106420740A (zh) 2009-02-23 2010-02-22 亚氨基糖以及治疗病毒性疾病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610416182.XA Pending CN106420740A (zh) 2009-02-23 2010-02-22 亚氨基糖以及治疗病毒性疾病的方法

Country Status (8)

Country Link
US (4) US8450345B2 (https=)
EP (1) EP2398321B1 (https=)
JP (3) JP5600329B2 (https=)
KR (2) KR20120042716A (https=)
CN (2) CN102655746B (https=)
CA (1) CA2753195C (https=)
ES (1) ES2579628T3 (https=)
WO (1) WO2010096764A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014MN02539A (https=) 2012-06-06 2015-07-24 Unither Virology Llc
KR20150128899A (ko) * 2013-03-15 2015-11-18 유니터 바이롤로지, 엘엘씨 항박테리아 화합물
KR20160055916A (ko) * 2013-09-16 2016-05-18 이머전트 바이롤로지 엘엘씨 데옥시노지리마이신 유도체 및 그의 이용 방법
CA2966893C (en) 2014-11-05 2023-10-24 Emergent Virology Llc Iminosugars
WO2017201052A1 (en) * 2016-05-16 2017-11-23 Emergent Virology Llc Methods of treating zika virus infection
KR101942757B1 (ko) 2017-08-23 2019-01-28 주식회사 유앤아이미트 마이크로웨이브를 이용한 n-노닐데옥시노지리마이신의 제조방법
CN113425720A (zh) * 2020-04-03 2021-09-24 深圳前海诺贝尔奖科学家技术转移转化有限公司 亚胺糖化合物在制备抗SARS-CoV-2病毒的药物中的用途
CN119841765B (zh) * 2025-01-09 2025-10-10 中南大学 Dnj衍生物、药物组合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1290168A (zh) * 1997-12-11 2001-04-04 牛津大学院长校长专家委员会 膜相关病毒复制的抑制
CN1694696A (zh) * 2002-09-23 2005-11-09 牛津大学校委会 亚氨基糖衍生物在抑制离子通道活性中的应用
US20070275998A1 (en) * 2006-05-24 2007-11-29 Butters Terry D Deoxynojirimycin and d-arabinitol analogs and methods of using

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555654A (en) 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2834122A1 (de) 1978-08-03 1980-02-14 Bayer Ag Verfahren zur herstellung von 6-amino-6-desoxy-l-sorbose
DE2839309A1 (de) 1978-09-09 1980-03-27 Bayer Ag 3,4,5-trihydroxypiperidin-derivate
DE2853573A1 (de) 1978-12-12 1980-07-03 Bayer Ag Herstellung von n-substituierten derivaten des l-desoxynojirimycins
DE3038901A1 (de) 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
DE3611841A1 (de) 1986-04-09 1987-10-15 Bayer Ag Verfahren zur herstellung von 1-desoxynojirimycin und dessen n-derivaten
US5043273A (en) 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US4994572A (en) 1989-10-12 1991-02-19 Monsanto Company Synthesis of nojirimycin derivatives
US5030638A (en) 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
US5200523A (en) 1990-10-10 1993-04-06 Monsanto Company Synthesis of nojirimycin derivatives
US5206251A (en) 1992-04-01 1993-04-27 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
WO1995022975A1 (en) 1994-02-25 1995-08-31 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
EP1714676A3 (en) 1998-02-12 2006-11-15 G.D. Searle LLC. Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
US6809083B1 (en) 1998-02-12 2004-10-26 Richard A. Mueller Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB9828474D0 (en) 1998-12-24 1999-02-17 British Aerospace Surface topology inspection
JP2002536407A (ja) 1999-02-12 2002-10-29 ジー・ディー・サール・アンド・カンパニー 肝炎ウィルス感染の治療のための置換−１，５−ジデオキシ−１，５−イミノ−ｄ−グルシトール化合物の使用
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
ATE234626T1 (de) 1999-07-26 2003-04-15 Searle & Co Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
PT2441467E (pt) 2003-01-31 2015-10-12 Sinai School Medicine Terapia combinada para o tratamento de transtornos associados a uma deficiência proteica
US7446098B2 (en) 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US20050256168A1 (en) 2004-04-28 2005-11-17 Block Timothy M Compositions for oral administration for the treatment of interferon-responsive disorders
US7524829B2 (en) 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
GB0501352D0 (en) 2005-01-21 2005-03-02 Slingsby Jason H Use of glycosylation modulators in combination with membrane fusion inhibitors for treatment of infections caused by viruses bearing glycosylated envelope
US7638488B2 (en) 2005-03-08 2009-12-29 Intermune, Inc. Use of alpha-glucosidase inhibitors to treat alphavirus infections
KR20080056688A (ko) 2005-03-16 2008-06-23 유니버시티 오브 옥스퍼드 Ｈｉｖ－ｉ용 만노스 면역원
EP2932982B1 (en) 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
KR20080031474A (ko) 2005-07-27 2008-04-08 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 안구 질환의 치료를 위한 열충격의 사용
US20070244184A1 (en) 2006-01-09 2007-10-18 Simon Fraser University Glycosidase inhibitors and methods of synthesizing same
AU2007241622A1 (en) 2006-04-24 2007-11-01 Academisch Medisch Centrum Improved treatment of cystic fibrosis
JP2009545621A (ja) 2006-08-02 2009-12-24 ユナイテッド セラピューティクス コーポレーション ウィルス感染症のリポソーム処置
US20080131398A1 (en) 2006-08-21 2008-06-05 United Therapeutics Corporation Combination therapy for treatment of viral infections
WO2008068548A1 (en) 2006-12-08 2008-06-12 Institut Necker Use of inhibitors of the glycosylation process for the prevention and treatment of genetic diseases
US8097728B2 (en) * 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
US20090252785A1 (en) 2008-03-26 2009-10-08 University Of Oxford Endoplasmic reticulum targeting liposomes
ES2562635T3 (es) 2009-02-24 2016-03-07 United Therapeutics Corporation Iminoazúcares y métodos de tratamiento de infecciones producidas por arenavirus
KR20120059447A (ko) 2009-03-27 2012-06-08 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 콜레스테롤 수준 저하 리포좀
CN102639133B (zh) 2009-06-12 2015-03-11 联合治疗公司 亚氨基糖和治疗布尼亚病毒性疾病以及披膜病毒性疾病的方法
WO2011028779A1 (en) 2009-09-04 2011-03-10 United Therapeutics Corporation Iminosugars and methods of treating filoviral diseases
KR101497194B1 (ko) 2009-09-04 2015-02-27 유나이티드 세러퓨틱스 코오포레이션 오르토믹소바이러스 감염의 치료 방법
CN102625801B (zh) 2009-09-04 2015-09-09 联合治疗公司 治疗痘病毒感染的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1290168A (zh) * 1997-12-11 2001-04-04 牛津大学院长校长专家委员会 膜相关病毒复制的抑制
CN1694696A (zh) * 2002-09-23 2005-11-09 牛津大学校委会 亚氨基糖衍生物在抑制离子通道活性中的应用
US20070275998A1 (en) * 2006-05-24 2007-11-29 Butters Terry D Deoxynojirimycin and d-arabinitol analogs and methods of using

Also Published As

Publication number Publication date
CA2753195C (en) 2015-06-02
ES2579628T3 (es) 2016-08-12
EP2398321A4 (en) 2012-01-04
JP5940607B2 (ja) 2016-06-29
US20130237567A1 (en) 2013-09-12
HK1165221A1 (zh) 2012-10-05
JP2014237706A (ja) 2014-12-18
EP2398321B1 (en) 2015-11-25
EP2398321A1 (en) 2011-12-28
US9943532B2 (en) 2018-04-17
KR20150038684A (ko) 2015-04-08
KR20120042716A (ko) 2012-05-03
KR101755133B1 (ko) 2017-07-06
US20170304333A1 (en) 2017-10-26
JP5600329B2 (ja) 2014-10-01
US20100222383A1 (en) 2010-09-02
CN106420740A (zh) 2017-02-22
US9044470B2 (en) 2015-06-02
US9579334B2 (en) 2017-02-28
CA2753195A1 (en) 2010-08-26
US8450345B2 (en) 2013-05-28
JP2012518649A (ja) 2012-08-16
US20150224128A1 (en) 2015-08-13
CN102655746A (zh) 2012-09-05
JP2016175937A (ja) 2016-10-06
WO2010096764A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
CN102655746B (zh) 亚氨基糖以及治疗病毒性疾病的方法
CN102625801B (zh) 治疗痘病毒感染的方法
JP5653438B2 (ja) オルトミクソウイルス感染の治療方法
CA2765086C (en) Iminosugars and methods of treating bunyaviral and togaviral diseases
CN102625660B (zh) 亚氨基糖以及治疗沙粒病毒感染的方法
JP5752689B2 (ja) フィロウイルス疾患を治療するイミノ糖および方法
HK1165221B (en) Iminosugars and methods of treating viral diseases
HK1165675B (en) Iminosugars and methods of treating arenaviral infections
HK1172209A (en) Iminosugars and methods of treating filoviral diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20161222

Address after: American Maryland

Patentee after: Imogen Ghent virology limited liability company

Patentee after: Univ Oxford

Address before: American Maryland

Patentee before: United Therapeutics Corp.

Patentee before: Univ Oxford

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160803

Termination date: 20190222

CF01 Termination of patent right due to non-payment of annual fee